Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined a busy slate of clinical catalysts and a growing commercial footprint during a presentation at TD Cowen’s 46th Annual Healthcare Conference, emphasizing a pipeline that management said includes roughly 21 or 22 drug candidates in clinical studies. Chief Executive Officer Chris Anzalone and Chief Medical Officer and Head of R&D […]

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined a busy slate of clinical catalysts and a growing commercial footprint during a presentation at TD Cowen’s 46th Annual Healthcare Conference, emphasizing a pipeline that management said includes roughly 21 or 22 drug candidates in clinical studies. Chief Executive Officer Chris Anzalone and Chief Medical Officer and Head of R&D […]